Literature DB >> 25004247

Germline FH mutations presenting with pheochromocytoma.

Graeme R Clark1, Marco Sciacovelli, Edoardo Gaude, Diana M Walsh, Gail Kirby, Michael A Simpson, Richard C Trembath, Jonathan N Berg, Emma R Woodward, Esther Kinning, Patrick J Morrison, Christian Frezza, Eamonn R Maher.   

Abstract

CONTEXT: At least a third of the patients with pheochromocytoma (PCC) or paraganglioma (PGL) harbor an underlying germline mutation in a known PCC/PGL gene. Mutations in genes (SDHB, SDHD, SDHC, and SDHA) encoding a component of the tricarboxylic acid cycle, succinate dehydrogenase (SDH), are a major cause of inherited PCC and PGL. SDHB mutations are also, albeit less frequently, associated with inherited renal cell carcinoma. Inactivation of SDH and another tricarboxylic acid cycle component, fumarate hydratase (FH), have both been associated with abnormalities of cellular metabolism, responsible for the activation of hypoxic gene response pathways and epigenetic alterations (eg, DNA methylation). However, the clinical phenotype of germline mutations in SDHx genes and FH is usually distinct, with FH mutations classically associated with hereditary cutaneous and uterine leiomyomatosis and renal cell carcinoma, although recently an association with PCC/PGL has been reported. OBJECTIVE AND
DESIGN: To identify potential novel PCC/PGL predisposition genes, we initially undertook exome resequencing studies in a case of childhood PCC, and subsequently FH mutation analysis in a further 71 patients with PCC, PGL, or head and neck PGL.
RESULTS: After identifying a candidate FH missense mutation in the exome study, we then detected a further candidate missense mutation (p.Glu53Lys) by candidate gene sequencing. In vitro analyses demonstrated that both missense mutations (p.Cys434Tyr and p.Glu53Lys) were catalytically inactive.
CONCLUSIONS: These findings 1) confirm that germline FH mutations may present, albeit rarely with PCC or PGL; and 2) extend the clinical phenotype associated with FH mutations to pediatric PCC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25004247     DOI: 10.1210/jc.2014-1659

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  57 in total

Review 1.  Targeting cancer vulnerabilities with high-dose vitamin C.

Authors:  Bryan Ngo; Justin M Van Riper; Lewis C Cantley; Jihye Yun
Journal:  Nat Rev Cancer       Date:  2019-05       Impact factor: 60.716

Review 2.  Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes.

Authors:  Rodrigo A Toledo; Patricia L M Dahia
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

Review 3.  Pheochromocytoma/Paraganglioma: Is This a Genetic Disorder?

Authors:  Lauren Fishbein
Journal:  Curr Cardiol Rep       Date:  2019-07-31       Impact factor: 2.931

4.  Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights.

Authors:  Maria I Carlo; A Ari Hakimi; Grant D Stewart; Gennady Bratslavsky; James Brugarolas; Ying-Bei Chen; W Marston Linehan; Eamonn R Maher; Maria J Merino; Kenneth Offit; Victor E Reuter; Brian Shuch; Jonathan A Coleman
Journal:  Eur Urol       Date:  2019-07-18       Impact factor: 20.096

Review 5.  Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis.

Authors:  Charlotte Lussey-Lepoutre; Alexandre Buffet; Aurélie Morin; Judith Goncalves; Judith Favier
Journal:  Cell Tissue Res       Date:  2018-02-09       Impact factor: 5.249

6.  A retrospective review of 48 individuals, including 12 families, molecularly diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC).

Authors:  Priya T Bhola; Cathy Gilpin; Amanda Smith; Gail E Graham
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

Review 7.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

Review 8.  Metabolism and immunity in breast cancer.

Authors:  Deyu Zhang; Xiaojie Xu; Qinong Ye
Journal:  Front Med       Date:  2020-10-19       Impact factor: 4.592

Review 9.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

10.  [Succinate dehydrogenase (SDH)-deficient renal cell carcinoma].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.